Can this new immunotherapy drug obliterate lower bowel cancer?
According to results from a trial conducted by five hospitals across the United Kingdom, doctors have discovered a new immunotherapy drug called ‘durvalumab’ that could do much more than just fight certain types of cancers in the lower part of the bowel.
This new treatment (which is given with radiotherapy and chemotherapy) has been found to destroy–not just suppress–cancers in the lower part of the bowel, removing the need for an operation in some patients.
This is huge news for rectal cancer patients, as surgery for this type of cancer often results in a ‘stoma’, which is a pouch that collects waste products outside of the body.
This surgery brings many risks, from infection to skin irritation and other problems.
The trial, which has 42 patients at five different hospitals in the UK, has not published a full set of findings. However, experts say the early results are promising.
One patient who benefited from this treatment was 75-year-old Paul Cusick, who was diagnosed with rectal cancer in January this year. The trial, called PRIME-RT, entails 12 weeks of radiotherapy, chemotherapy and ‘durvalumab’ infusions.
The doctors wished to decrease the tumour size before surgery, but by June, Paul’s scans showed no trace of cancer.
Professor Mark Saunders, a consultant clinical oncologist at The Christie Hospital in Manchester–which is running the trial–said, ‘We’ve had quite a number of patients who now don’t need surgery, which is very promising, but we have to follow them up for a little while longer.’
Another study from last year has proven that ‘durvalumab’ can destroy rectal tumours in patients with a specific type of cancer.
Additionally, the drug has been used as a treatment for certain types of lung cancer and has shown promise in the treatment of endometrial and stomach cancers.
As for Paul, he’s looking forward to returning to work later this year and expressed: ‘I’ve been healthy all my life, so getting the diagnosis was a real shock. I’m obviously delighted that the cancer appears to have completely disappeared, and I don’t have to have an operation.’
‘I didn’t really have any serious side-effects, so the experience has been really good,’ he added.
What do you think of this story, members? Share your thoughts in the comments below!
This new treatment (which is given with radiotherapy and chemotherapy) has been found to destroy–not just suppress–cancers in the lower part of the bowel, removing the need for an operation in some patients.
This is huge news for rectal cancer patients, as surgery for this type of cancer often results in a ‘stoma’, which is a pouch that collects waste products outside of the body.
This surgery brings many risks, from infection to skin irritation and other problems.
The trial, which has 42 patients at five different hospitals in the UK, has not published a full set of findings. However, experts say the early results are promising.
One patient who benefited from this treatment was 75-year-old Paul Cusick, who was diagnosed with rectal cancer in January this year. The trial, called PRIME-RT, entails 12 weeks of radiotherapy, chemotherapy and ‘durvalumab’ infusions.
The doctors wished to decrease the tumour size before surgery, but by June, Paul’s scans showed no trace of cancer.
Professor Mark Saunders, a consultant clinical oncologist at The Christie Hospital in Manchester–which is running the trial–said, ‘We’ve had quite a number of patients who now don’t need surgery, which is very promising, but we have to follow them up for a little while longer.’
Another study from last year has proven that ‘durvalumab’ can destroy rectal tumours in patients with a specific type of cancer.
Additionally, the drug has been used as a treatment for certain types of lung cancer and has shown promise in the treatment of endometrial and stomach cancers.
As for Paul, he’s looking forward to returning to work later this year and expressed: ‘I’ve been healthy all my life, so getting the diagnosis was a real shock. I’m obviously delighted that the cancer appears to have completely disappeared, and I don’t have to have an operation.’
‘I didn’t really have any serious side-effects, so the experience has been really good,’ he added.
Key Takeaways
- A new immunotherapy drug, ‘durvalumab’, could spare some bowel cancer patients from undergoing life-altering surgery.
- In the trial where 42 patients enrolled, the drug was effective, showing promising early results.
- Combined with radiotherapy and chemotherapy, ‘durvalumab’ can eliminate cancers in the lower part of the bowel, eliminating the need for surgery.
- The procedure's effectiveness can be seen in the case of Paul Cusick, a 75-year-old patient diagnosed with rectal cancer whose tumour disappeared completely after being treated with this therapy.
What do you think of this story, members? Share your thoughts in the comments below!